Basilard Biotech is a firm established in Southern California that is prepared to lead a revolution in the engineering of cell-based medicines in the field of Cell and Gene Therapy (CGT). 

CellettoTM, the company’s innovative gene delivery technology platform, was unveiled in 2019. This unique technique to nanomechanical gene delivery has the potential to overcome the present limits of viral and non-viral gene delivery, paving the way for more scalable and cost-effective cell and gene therapy manufacturing.

Youtube video {https://youtu.be/-BNZ8WDLlII}

A highly skilled team leads the startup with solid experience in the medical field. The company was founded with the belief that health care professionals and patients should have access to the most recent advances in technology to prevent, diagnose, and treat diseases.

By utilising the strength and diversity of cell activities, cell and gene therapies hold enormous promise to solve unmet therapeutic needs. They are the best hope for discovering cures to the world’s most prevalent diseases, impacting millions of people and killing them. The key hurdles presently include reducing biological and ex-vivo gene delivery restrictions and scaling production (cost-effectively) to satisfy the demands of existing and future cell treatments.

Because it is generally recognised that viral vectors will not be a feasible long-term option due to their high cost, lag time, and supply chain restrictions, gene delivery is becoming an increasingly crucial bottleneck in creating many Cell and Gene Therapies (CGT). 

The demand for new, better non-viral delivery options is driven by awareness of this constraint. Basilard now aims to seize this opportunity. They look forward to assisting in the development of current go-to-market strategies and the discovery, development, and production of the next generation of innovative CGTs.

A New Approach to Gene Delivery

CellettoTM overcomes this barrier with its novel, unique, IP-protected mechanoporation method, which takes a mechanical (rather than biological) approach to gene delivery. CellettoTM can transport practically any gene to the nucleus of a cell in bulk without jeopardising its survival. 

CellettoTM introduces a disruptive new paradigm that will transform the engineering of cell-based therapies by lowering costs and increasing versatility in comparison to current biological delivery methods (e.g., viral vectors) and increasing efficiency and safety compared to existing ones and emerging chemical and physical processes.

Celletto™ is a Deterministic Mechanoporation (DMP) gene delivery technology platform introduced by Bailard Biotech Inc. Fluid flow is used by DMP to drag each suspended cell onto its specialised nanoscale needle, inducing poration of both nuclear membranes and the plasma. By reversing flow, the cells are pushed off the needles, and the load is delivered by diffusion via the single transitory pore created in each cell.

The Innovative Technology 

The company’s technique is remarkable because of its unique capacity to create a single pore in both the plasma and nuclear membranes of every cell in a vast population safely and exactly. This is critical since it enables them to:

• High cellular viability AND high delivery efficiency
• Intranuclear administration by direct injection
• Perform the same treatment of all cells.

Author: Sharjeel

Sharjeel joined Startempire Wire as emerging technologies editor. Earlier, he worked at Silicon Canals, a leading English language technology media source for the Benelux and wider Europe. He covered the European technology and startup ecosystem digging into latest funding rounds of startups.